Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Benzinga · 1d ago
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.